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METHODS & CONCEPTS
PMC1
TRANSFERABILITY OF ECONOMIC EVALUATIONS: CAN
RESULTS FROM ONE GEOGRAPHIC AREA BE USED TO HELP
INFORM HEALTH CARE DECISION MAKING IN ANOTHER?
Goeree RA1, Burke N1, Bradford A1, Manca A2, Blackhouse G1,
O’Reilly D1,Tarride JE1
1McMaster University, Hamilton, ON, Canada, 2University of York,York,
UK
There has been increasing pressure to consider using published
economic evaluations or health technology assessments from
other jurisdictions for local reimbursement decisions. Geogra-
phic transferability has the potential to facilitate assessments that
would otherwise be infeasible and the potential to make more
efﬁcient use of global evaluation resources. OBJECTIVES: To
review and summarize the literature on: 1) factors affecting geo-
graphic transferability of economic evaluation data; 2) criteria,
guidelines or decision rules for determining transferability poten-
tial; and 3) approaches which have either been proposed or used
in practice for transferability. METHODS: A systematic litera-
ture review on transferability was conducted. Electronic data-
bases, hand searching and bibliographic searching techniques
were utilized. Two classiﬁcation systems were developed; one
summarizing transferability factors, and another summarizing
transferability approaches. RESULTS: Titles and abstracts of
nearly 5000 articles were reviewed and 808 in full text. There
was a substantial literature identifying over 70 factors potentially
affecting transferability. From these papers we developed a clas-
siﬁcation system which grouped these factors into ﬁve broad cat-
egories based on characteristics of the patient, the disease, the
provider, the health care system and methodological conven-
tions. Only three papers were identiﬁed that proposed criteria,
guidelines or decision rules for determining transferability poten-
tial and 38 empirical studies attempted to transfer economic
evaluation data from one country to another. CONCLUSIONS:
There is strong evidence indicating that transferability of eco-
nomic evaluation data is complex and can result in misleading
results. The subjective nature of the proposed systems for deter-
mining transferability potential highlights the need for additional
research. Approaches which have been used for transferability
suggest that there is a need for country-speciﬁc substitution of
practice pattern data as well as unit cost data. The results from
this review will assist researchers and government decision
making bodies when considering and conducting transferability
studies.
PMC2
HEALTH CONDITIONS IN POSTMENOPAUSAL WOMEN AND
IMPLICATIONS FOR THE DESIGN OF CLINICAL TRIALS OF
AROMATASE INHIBITORS
Zhang D1, Carlson A2, Kulig K3,Wagner S3
1University of Minnesota, Minneapolis, MN, USA, 2Data Intelligence
Consultants, LLC, Eden Prairie, MN, USA, 3Pﬁzer Global
Pharmaceuticals, New York, NY, USA
OBJECTIVES: To establish reference levels within the US popu-
lation of postmenopausal women for conditions often evaluated
in clinical trials of aromatase inhibitors for the treatment of
breast cancer. METHODS: The prevalence of selected health
conditions was estimated using the 2002 Medical Conditions ﬁle
from the Medical Expenditure Panel Survey (MEPS). The study
cohort included women 55 to 85 years of age, without cancer or
cancer related activity, and without hormone replacement
therapy in 2002. Conditions of interest included osteoporosis,
fractures, joint related problems, and lipid disorders. Estimated
prevalence rates from MEPS were compared with those reported
in clinical trials of AIs identiﬁed from Medline and other sources.
RESULTS: A total of 2723 MEPS survey respondents represent-
ing 20.4 million US women aged 55 to 85 years were included
in the prevalence estimation sample. The most prevalent condi-
tion of interest was joint-related problems other than rheuma-
toid arthritis and osteoarthritis (34.1%, SE = 0.9%); 22.7% (SE
= 1.1%) reported dyslipidemia; 10.3% (SE = 0.8%) reported
osteoporosis, and 6.0% (SE = 0.6) reported fractures. CON-
CLUSIONS: The results of this study suggest that conditions
evaluated in clinical trials of aromatase inhibitors are commonly
found within the US population of postmenopausal women.
Moving forward it will be important to collect baseline infor-
mation on the presence of these conditions in women with breast
cancer enrolled in clinical studies of AIs in order to correctly
interpret the potential impact of this treatment on these 
conditions.
PMC3
HOW MUCH DOES A DAY IN THE HOSPITAL COST?
Candrilli S, Mauskopf J
RTI Health Solutions, Research Triangle Park, NC, USA
OBJECTIVE: There are standard data sources for estimating the
costs of inpatient and outpatient physician procedures, outpa-
tient visits, and drug costs for the US, but no standard data
source for estimating the average cost per day in the hospital at
various levels of care (i.e., intensive or critical care units
(ICU/CCU), regular care). METHODS: A method for estimating
the cost per day in the hospital for different levels of care and
different diagnoses was developed using data from the Health-
care Cost and Utilization Project’s (HCUP) 2002 Michigan State
Inpatient Database (SID). Linear regression models without an
intercept were used to estimate the relationship between total
cost and length of stay at each level of care for selected diagno-
sis-related groups (DRGs). RESULTS: Nearly 1.3 millions inpa-
tient stays were initially included in the Michigan SID. Across
all records with complete data (n = 787,753), the incremental
cost per day, in 2005 dollars, in the hospital, for all medical con-
ditions, was $1237 (SE = $0.97). The incremental cost per day
by level of care across all conditions was $2401 (SE = $3.60) in
an ICU or CCU and $1122 (SE = $0.97) in regular care. The
incremental cost per day in an ICU or CCU varied across DRGs
analyzed, ranging from $1241 (SE = $18.27) for DRG 387 (n =
1422), prematurity with major problems, to $3,315 (SE =
$106.60) for DRG 105 (n = 1220), cardiac valve and other major
cardiothoracic procedures without cardiac catheterization. The
incremental cost per day in regular care varied from $504.94 (SE
= $4.67) for DRG 379 (n = 1789), threatened abortion, to $3081
(SE = $119.23) for DRG 106 (n = 164), coronary bypass with
PTCA. CONCLUSIONS: A simple regression analysis method
can be used with data from national or state inpatient datasets
to estimate average cost per day in the hospital at different levels
of care and for different diagnoses. These estimates can be used
in cost-effectiveness studies.
PMC4
THE LEVEL OF AWARENESS OF TMC PHYSICIANS ON THE
PRICES OF COMMONLY PRESCRIBED MEDICATIONS AND
DIAGNOSTIC PROCEDURES AND ITS EFFECT ON THEIR
PRESCRIBING PREFERENCES
The JJA,Avelino MMS, Roxas AAJ
The Medical City, Pasig, NCR, Philippines
OBJECTIVE: To determine the level of awareness of The
Medical City (TMC) physicians on the prices of commonly 
prescribed medications for common causes of illnesses and 
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commonly prescribed diagnostic tests and to know its effect on
their prescribing preferences. METHODS: This study is a
descriptive cross-sectional survey which includes data gathering
through questionnaire, retrieval, tabulating, and interpreting of
results a probability stratiﬁed random sampling of 125 TMC
physicians (regular consultants, fellows, and residents) was done.
The sample size was computed using the Lynche formula. The
physicians were stratiﬁed by specialties which include Internal
Medicine, Surgery, Pediatrics, Obstetrics and Gynecology, Oph-
thalmology, and ENT-Head and Neck Surgery and were asked
to answer a pre-tested questionnaire. Non-respondents were sent
another questionnaire for them to answer to increase response
rate. The collected data were analyzed using the percentage and
weighted average and one-way analysis of variance. Inferential
analysis was done using ANOVA. SPSS software was used for
these purposes. RESULTS: Verbal interpretation of the descrip-
tive statistics shows that all respondent physicians agree to the
statement that the prices of medications and diagnostic tests are
important factors which inﬂuence them in their practice. Fur-
thermore, the respondent physicians believe that physicians
should know the prices of medications and tests they prescribe
or order. They also consider the economic status of their patients
in their practice. However, descriptive data based on the mean
price estimates from all specialties, whether residents, fellows, or
consultants, show signiﬁcant difference in the physician per-
ceived prices of commonly prescribed and ordered medications
and diagnostic tests and the actual TMC prices of such medica-
tions and tests (p value >0.05) thereby rejecting the null hypoth-
esis saying otherwise. CONCLUSION: The Medical City
physician is not aware of the prices of medications and diag-
nostic tests he commonly prescribes or orders.
PMC5
ARE NON-INFERIORITY TRIALS SUITABLE FOR ECONOMIC
EVALUATION? ESTIMATION IS STILL MORE IMPORTANT
THAN HYPOTHESIS TESTING
Briggs A1, Backhouse M2
1University of Glasgow, Glasgow, UK, 2Novartis Pharmaceuticals, Basel,
Switzerland
OBJECTIVES: The use of cost-minimisation analysis, based on
a negative result from a clinical trial, has recently been ques-
tioned. Instead, it has been argued that cost-minimisation analy-
sis should only be undertaken as part of an equivalence trial,
designed to conﬁrm the absence of a meaningful difference
between treatments. The “non-inferiority” trial is becoming a
popular method of comparing a new treatment to an existing
standard as non-inferiority may be an acceptable outcome for
licensing purposes. Non-inferiority trials are designed to show
that a new treatment is no less effective than an existing treat-
ment—in reality, it may be more effective or have a similar effect
(within a margin of clinical equivalence). METHODS: In this
paper, the role of the non-inferiority trial design is critically
appraised as a vehicle for economic evaluation. RESULTS: A
number of issues are noted in relation to non-inferiority designs
that limit their usefulness for making judgements concerning the
value for money of treatments. The margin of clinical equiva-
lence is essentially arbitrary and is rendered meaningless once
costs (both in terms of resources and the health effects of any
adverse events) are considered. From an economic perspective,
acceptance of a new treatment can only be recommended if the
new treatment is both “non-inferior” in both clinical and cost
terms, however, the role of the margin of clinical equivalence
(and potentially a similar margin of cost equivalence) serves 
to cloud the comparison with the traditional concept of 
“dominance” in economic studies. CONCLUSION: The design
of trial in terms of “superiority” or “non-inferiority” does not
change the fact that separate and sequential tests of hypothesis
for costs and effects independently are to be avoided in economic
evaluation. The recommendation remains that estimation and
not hypothesis testing should be the key to interpreting cost-
effectiveness studies of new treatments.
PMC6
PMC7
A STANDARDIZED METHODOLOGY TO MEASURE MEDICINE
PRICES,AVAILABILITY,AFFORDABILITY AND PRICE
COMPONENTS IN DEVELOPING AND TRANSITIONAL
COUNTRIES
Kotwani A1, Ewen M2, Laing R3
1Vallabhbhai Patel Chest Institute, University of Delhi, Delhi, India,
2Health Action International Europe, Amsterdam,The Netherlands,
3WHO, Geneva, Switzerland
OBJECTIVES: In developing countries, medicines are the largest
proportion of out-of-pocket health expenses as medicines are
rarely subsidized. Medicine prices are variable and often high
and as a result medicines are frequently unaffordable for a large
proportion of the global population. In 2003, the World Health
Organisation and Health Action International (HAI) published
a manual entitled “Medicine Prices—a new approach to mea-
surement”. This innovative manual describes a method to collect
price information reliably, facilitating national and international
comparisons. METHODS: The process involves the collection of
retail price and availability data from a sample of registered
pharmacies in the public, private or “other” sector, in each of
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